Clinical Trial

A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation

Study acronym: Siltux-AMR
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Antibody-mediated rejection after lung transplantation commonly results in allograft failure and death in spite of current therapeutic regimens. We are testing the safety and tolerability of the addition of a novel immunosuppressive medication to routine treatment for antibody-mediated rejection. Future studies will be needed to assess efficacy if this study demonstrates safety
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-18; most recent amendment 2025-12-30.
Status change: Not Yet Recruiting → Recruiting 2025-12-17
Trial Details
NCT Number NCT06990711
Lead Sponsor Washington University School of Medicine
Collaborators: National Heart, Lung, and Blood Institute (NHLBI), University of Utah
Conditions Antibody Mediated Rejection of Lung Transplant
Enrollment 30 participants
Start Date 2025-11-06
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-31